{
  "protocol_version": "evo-1.0",
  "session_id": "evo_20260213_214547_pharmacology",
  "timestamp": "2026-02-13T21:47:48.611264+00:00",
  "question": "Does the supramolecular organization of VDAC1 in the outer mitochondrial membrane \u2014 specifically its lipid-dependent transition between dense honeycomb arrays and dispersed monomers \u2014 determine the pharmacological outcome of VDAC-binding drugs? Recent AFM and molecular dynamics studies (2024-2025) show that: (a) cholesterol and PE stabilize VDAC1 honeycomb assemblies, (b) cardiolipin disrupts these assemblies, freeing VDAC monomers, and (c) VDAC preferentially localizes to cardiolipin-rich OMM-IMM contact sites. Given these findings: (1) Does the Chol/CL ratio in the OMM physically determine the fraction of VDAC1 in honeycomb-protected vs dispersed-oligomerization-competent states, and is this the biophysical basis of the apoptotic threshold equation Threshold = K/[(1-f_HKII)(1-f_BclxL)]*(Chol/CL)? (2) Does HK-II displacement from VDAC1 promote honeycomb disassembly by unmasking cardiolipin microdomains, thereby converting protected VDAC arrays into oligomerization-competent monomers? (3) Can lipophilic drugs (CBD logP 6.3, statins logP 4-5) alter VDAC supramolecular organization by changing local membrane order, independent of direct protein binding \u2014 and would this constitute a previously unrecognized mechanism of VDAC pharmacology? (4) Does the honeycomb-to-dispersed transition represent the physical instantiation of the point of no return in VDAC-mediated apoptosis \u2014 i.e., is oligomerization only possible from the dispersed state, making membrane reorganization the rate-limiting step rather than any single molecular binding event?",
  "convergence_report": {
    "s1_initial": {
      "n_models_responded": 5,
      "initial_jaccard": 0.047136752136752134,
      "initial_cosine": 0.8412853658199311
    },
    "s2_refinement": {
      "total_rounds": 0,
      "early_stopped": false,
      "final_jaccard": 0.0,
      "final_cosine": 0.0,
      "final_jsd": 0.0,
      "final_type_01_ratio": 0.0
    },
    "s3_gate": {
      "passed": true,
      "jaccard": 0.6523,
      "type_01_ratio": 0.8,
      "recommendation": ""
    }
  },
  "verification": {
    "n_type2_input": 10,
    "n_promoted": 1,
    "n_held": 3,
    "n_novel": 4,
    "n_contradicted": 2,
    "total_calls": 10
  },
  "gate": {
    "passed": true,
    "n_passed": 10,
    "n_failed": 8,
    "recommendation": "Lab Gate PASSED with filter. 10/18 claims cleared. 8 filtered: 'The proposed threshold equation Threshold = K/[(1-...' not feasible; 'Honeycomb\u2192dispersed transition instantiates apopto...' not feasible; 'Honeycomb\u2192dispersed transition instantiates apopto...' lacks novelty",
    "claims": [
      {
        "statement": "The Chol/CL ratio is a primary determinant of the honeycomb-vs-dispersed VDAC1 equilibrium in recons",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "The proposed threshold equation Threshold = K/[(1-f_HKII)(1-f_BclxL)]*(Chol/CL) is a plausible pheno",
        "falsifiable": true,
        "feasible": false,
        "novel": true,
        "passed": false
      },
      {
        "statement": "HK-II displacement unmasks VDAC N-terminal and membrane-proximal regions that preferentially recruit",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Lipophilic drugs (CBD, statins) can alter VDAC supramolecular organization through membrane order pe",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "The Chol/CL ratio in the OMM physically determines the fraction of VDAC1 in honeycomb vs. dispersed ",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "HK-II displacement from VDAC1 promotes honeycomb disassembly by unmasking cardiolipin microdomains, ",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Lipophilic drugs (e.g., CBD, statins) alter VDAC1 supramolecular organization by changing local memb",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "The honeycomb-to-dispersed transition is the physical \"point of no return\" for VDAC-mediated apoptos",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Chol/CL ratio physically determines VDAC1 fraction in honeycomb (protected) vs. dispersed (oligomeri",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "HK-II displacement from VDAC1 unmasks CL microdomains, promoting honeycomb disassembly to oligomeriz",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Lipophilic drugs like CBD (logP 6.3; Kd=11\u03bcM) or statins (logP 4-5) alter VDAC organization by incre",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Honeycomb\u2192dispersed transition instantiates apoptotic point of no return, with oligomerization restr",
        "falsifiable": true,
        "feasible": false,
        "novel": false,
        "passed": false
      },
      {
        "statement": "The OMM Chol/CL ratio is a primary determinant of the apoptotic threshold by physically controlling ",
        "falsifiable": false,
        "feasible": false,
        "novel": false,
        "passed": false
      },
      {
        "statement": "The dissociation of HK-II from VDAC1 is a critical sensitizing step that unmasks local cardiolipin p",
        "falsifiable": false,
        "feasible": false,
        "novel": false,
        "passed": false
      },
      {
        "statement": "The Chol/CL ratio is a primary physical determinant of the VDAC1 honeycomb-vs-monomer equilibrium, a",
        "falsifiable": false,
        "feasible": false,
        "novel": false,
        "passed": false
      },
      {
        "statement": "HK-II binding stabilizes honeycomb arrays by masking/displacing cardiolipin from VDAC's vicinity; it",
        "falsifiable": false,
        "feasible": false,
        "novel": false,
        "passed": false
      },
      {
        "statement": "Lipophilic drugs with logP >4 can alter VDAC supramolecular organization indirectly by modulating lo",
        "falsifiable": false,
        "feasible": false,
        "novel": false,
        "passed": false
      },
      {
        "statement": "The honeycomb-to-dispersed transition is the physical rate-limiting step for VDAC-mediated apoptosis",
        "falsifiable": false,
        "feasible": false,
        "novel": false,
        "passed": false
      }
    ]
  },
  "hypotheses": [
    {
      "id": "H1",
      "prediction": "IF VDAC1 is reconstituted into supported lipid bilayers with Chol/CL molar ratios ranging from 0.5 to 10, THEN AFM imaging will reveal a monotonic increase in honeycomb array area fraction (f_h) from <0.15 at Chol/CL=0.5 to >0.70 at Chol/CL=10, with a Hill-type transition midpoint at Chol/CL \u2248 2-4.",
      "testability_score": 8.0,
      "key_variables": [],
      "parameters": [
        {
          "name": "VDAC1_density",
          "range": "500.0-5000.0 monomers/\u03bcm\u00b2",
          "distribution": "uniform"
        },
        {
          "name": "PE_fraction",
          "range": "0.2-0.45 mol",
          "distribution": "uniform"
        },
        {
          "name": "temperature",
          "range": "22.0-37.0 \u00b0C",
          "distribution": "uniform"
        },
        {
          "name": "CL_mol_percent",
          "range": "2.0-20.0 mol%",
          "distribution": "uniform"
        },
        {
          "name": "Hill_coefficient",
          "range": "1.0-4.0 dimensionless",
          "distribution": "uniform"
        }
      ],
      "monte_carlo": {
        "effect_size": 0.8117,
        "power": 1.0,
        "converged": "True",
        "outcome_stats": {
          "effect_magnitude": {
            "mean": 0.4996434455974755,
            "std": 0.12255297031415406,
            "median": 0.5032191473846219,
            "ci_lower": 0.25830920877384034,
            "ci_upper": 0.7414176430071063,
            "min": 0.15758184713280732,
            "max": 0.8156161995315161
          }
        }
      }
    },
    {
      "id": "H3",
      "prediction": "IF CBD (1-10 \u03bcM) is added to VDAC1-containing reconstituted bilayers, THEN honeycomb array density will change by \u226530% at concentrations below the Kd for direct VDAC binding (11 \u03bcM), AND this effect will be reproduced by a membrane-order-matched control compound (e.g., cholesterol hemisuccinate or vitamin E) that does not bind VDAC, AND will NOT be abolished by VDAC1 point mutations (e.g., E73Q, T19A) that disrupt known drug-binding pockets.",
      "testability_score": 7.0,
      "key_variables": [],
      "parameters": [
        {
          "name": "CBD_concentration",
          "range": "0.1-30.0 \u03bcM",
          "distribution": "uniform"
        },
        {
          "name": "CBD_Kd_VDAC",
          "range": "5.0-20.0 \u03bcM",
          "distribution": "uniform"
        },
        {
          "name": "f_h_change_at_subKd",
          "range": "0.0-60.0 %",
          "distribution": "uniform"
        },
        {
          "name": "logP_matched_control",
          "range": "5.0-7.0 (uniform)",
          "distribution": "uniform"
        },
        {
          "name": "partition_coefficient_OMM",
          "range": "100.0-10000.0 (log-uniform)",
          "distribution": "uniform"
        }
      ],
      "monte_carlo": {
        "effect_size": 0.9216,
        "power": 1.0,
        "converged": "True",
        "outcome_stats": {
          "effect_magnitude": {
            "mean": 0.4934038742106948,
            "std": 0.1322364803274733,
            "median": 0.4865524462283509,
            "ci_lower": 0.258863510308399,
            "ci_upper": 0.7579434521888676,
            "min": 0.15250645903437524,
            "max": 0.8466002656183298
          }
        }
      }
    },
    {
      "id": "H2",
      "prediction": "IF HK-II is displaced from VDAC1 honeycomb arrays (by glucose-6-phosphate or clotrimazole treatment), THEN within 10-30 minutes: (a) CL-specific fluorescent probe (NAO or TopFluor-CL) signal at VDAC clusters increases \u22652-fold, and (b) honeycomb array area fraction decreases by \u226540%, and (c) both effects are abolished by prior CL depletion (PLS3 knockdown or CL synthase inhibition).",
      "testability_score": 6.0,
      "key_variables": [],
      "parameters": [
        {
          "name": "II_displacement_rate",
          "range": "0.01-0.5 min\u207b\u00b9",
          "distribution": "uniform"
        },
        {
          "name": "CL_exposure_fold_change",
          "range": "1.0-5.0 fold",
          "distribution": "uniform"
        },
        {
          "name": "f_h_decrease",
          "range": "0.0-80.0 %",
          "distribution": "uniform"
        },
        {
          "name": "clotrimazole_EC50",
          "range": "1.0-20.0 \u03bcM",
          "distribution": "uniform"
        },
        {
          "name": "G6P_concentration",
          "range": "0.5-10.0 mM",
          "distribution": "uniform"
        },
        {
          "name": "time_to_disassembly",
          "range": "5.0-60.0 min",
          "distribution": "uniform"
        },
        {
          "name": "CL_content_threshold",
          "range": "2.0-8.0 mol%",
          "distribution": "uniform"
        }
      ],
      "monte_carlo": {
        "effect_size": 0.8146,
        "power": 1.0,
        "converged": "True",
        "outcome_stats": {
          "effect_magnitude": {
            "mean": 0.5047811454075062,
            "std": 0.11697162177573682,
            "median": 0.5160573620423872,
            "ci_lower": 0.25178517706886544,
            "ci_upper": 0.7345913684994891,
            "min": 0.18763964952478188,
            "max": 0.8309388969847998
          }
        }
      }
    },
    {
      "id": "H4",
      "prediction": "IF the honeycomb-to-dispersed transition is the rate-limiting step for apoptosis, THEN: (a) pre-dispersing VDAC arrays (by CL enrichment or cholesterol extraction with M\u03b2CD) will accelerate cytochrome c release by \u22653-fold compared to apoptotic stimulus alone, (b) artificially stabilizing honeycombs (cholesterol loading) will delay cytochrome c release by \u22653-fold even in the presence of BH3-only protein activation, and (c) the time from stimulus to cytochrome c release will correlate with f_h decay kinetics (r\u00b2 > 0.7) rather than with Bax/Bak activation kinetics.",
      "testability_score": 5.0,
      "key_variables": [],
      "parameters": [],
      "monte_carlo": {
        "effect_size": 0.0,
        "power": 0.0,
        "converged": true,
        "outcome_stats": {
          "effect_magnitude": {
            "mean": 0.5,
            "std": 0.0,
            "median": 0.5,
            "ci_lower": 0.5,
            "ci_upper": 0.5,
            "min": 0.5,
            "max": 0.5
          }
        }
      }
    }
  ],
  "simulations": {
    "n_hypotheses_simulated": 4,
    "total_iterations": 1200,
    "llm_calls": 0,
    "results": [
      {
        "hypothesis_id": "H1",
        "n_iterations": 300,
        "effect_size": 0.8117,
        "power": 1.0,
        "converged": "True",
        "parameters": {
          "VDAC1_density": {
            "mean": 2689.9406972118127,
            "std": 1304.198896547443,
            "median": 2655.5188171298764,
            "ci_lower": 624.6036697890011,
            "ci_upper": 4838.779150412854,
            "min": 533.1302138795248,
            "max": 4965.690038251267
          },
          "PE_fraction": {
            "mean": 0.3263299037821169,
            "std": 0.07095438619794195,
            "median": 0.32837026434964656,
            "ci_lower": 0.20902717512014918,
            "ci_upper": 0.4450301055900124,
            "min": 0.20135745853217513,
            "max": 0.4497761826185597
          },
          "temperature": {
            "mean": 29.45799365199565,
            "std": 4.467470552435863,
            "median": 29.531569732842947,
            "ci_lower": 22.256456004567635,
            "ci_upper": 36.760399057723724,
            "min": 22.018495937678622,
            "max": 36.98115055100147
          },
          "CL_mol_percent": {
            "mean": 11.202044024184227,
            "std": 5.249743428113614,
            "median": 10.836788257129141,
            "ci_lower": 2.766627992691875,
            "ci_upper": 19.70340848851338,
            "min": 2.0093373949826994,
            "max": 19.98959436603538
          },
          "Hill_coefficient": {
            "mean": 2.4934596393390187,
            "std": 0.879184054162143,
            "median": 2.458709032439286,
            "ci_lower": 1.1114630944974861,
            "ci_upper": 3.927462460834703,
            "min": 1.0032023950682416,
            "max": 3.9900316345574605
          }
        }
      },
      {
        "hypothesis_id": "H2",
        "n_iterations": 300,
        "effect_size": 0.8146,
        "power": 1.0,
        "converged": "True",
        "parameters": {
          "II_displacement_rate": {
            "mean": 0.2541558734523162,
            "std": 0.13968494363096823,
            "median": 0.25249782123264974,
            "ci_lower": 0.022915441480077403,
            "ci_upper": 0.4858359377935639,
            "min": 0.011543574855015908,
            "max": 0.49896205469431903
          },
          "CL_exposure_fold_change": {
            "mean": 2.983222378162559,
            "std": 1.1425354795026155,
            "median": 3.0123466508321557,
            "ci_lower": 1.0849410217246303,
            "ci_upper": 4.871193887529913,
            "min": 1.0088819882565003,
            "max": 4.982330646062524
          },
          "f_h_decrease": {
            "mean": 40.071833057767535,
            "std": 22.84846461013696,
            "median": 38.40172142057604,
            "ci_lower": 2.724172859926748,
            "ci_upper": 78.20728185742524,
            "min": 1.3464250564507818,
            "max": 79.82736326636902
          },
          "clotrimazole_EC50": {
            "mean": 10.657532131065539,
            "std": 5.656535488211213,
            "median": 11.110160877762558,
            "ci_lower": 1.4239001677092777,
            "ci_upper": 19.47256591895715,
            "min": 1.107032084049457,
            "max": 19.96193568108809
          },
          "G6P_concentration": {
            "mean": 5.3466572199557705,
            "std": 2.8357433753830565,
            "median": 5.494840876857587,
            "ci_lower": 0.8778647728150258,
            "ci_upper": 9.853847994040326,
            "min": 0.542182046527137,
            "max": 9.97747314470912
          },
          "time_to_disassembly": {
            "mean": 32.81401993757957,
            "std": 15.90227710258287,
            "median": 32.69494817776653,
            "ci_lower": 6.1697512130187535,
            "ci_upper": 58.18582182771039,
            "min": 5.351308893808621,
            "max": 59.89726925647036
          },
          "CL_content_threshold": {
            "mean": 5.085872929523894,
            "std": 1.7449872319621158,
            "median": 5.135116150308675,
            "ci_lower": 2.165138203630283,
            "ci_upper": 7.9050934953818235,
            "min": 2.0273257286635853,
            "max": 7.997319576845403
          }
        }
      },
      {
        "hypothesis_id": "H3",
        "n_iterations": 300,
        "effect_size": 0.9216,
        "power": 1.0,
        "converged": "True",
        "parameters": {
          "CBD_concentration": {
            "mean": 14.674726780346761,
            "std": 8.61916532316488,
            "median": 13.928295492957716,
            "ci_lower": 1.2215562505880107,
            "ci_upper": 29.182343258385696,
            "min": 0.2643102479547169,
            "max": 29.86203201769135
          },
          "CBD_Kd_VDAC": {
            "mean": 12.26712657458875,
            "std": 4.405503341556564,
            "median": 12.06575895624245,
            "ci_lower": 5.3740259174088125,
            "ci_upper": 19.548761925608577,
            "min": 5.01929376936122,
            "max": 19.891742914984732
          },
          "f_h_change_at_subKd": {
            "mean": 28.914901213725486,
            "std": 17.72241163152914,
            "median": 27.65202377805043,
            "ci_lower": 1.5689369766331567,
            "ci_upper": 58.28183826935681,
            "min": 0.1994289156412421,
            "max": 59.687945470356894
          },
          "logP_matched_control": {
            "mean": 5.938655910074936,
            "std": 0.5635179286525577,
            "median": 5.875257563848154,
            "ci_lower": 5.042930128246091,
            "ci_upper": 6.90343356143155,
            "min": 5.0008653010921655,
            "max": 6.994119804057614
          },
          "partition_coefficient_OMM": {
            "mean": 5484.137122696184,
            "std": 2975.3775965085865,
            "median": 5940.206751360467,
            "ci_lower": 465.6299661570676,
            "ci_upper": 9758.04166132791,
            "min": 112.59782757831107,
            "max": 9948.571501947692
          }
        }
      },
      {
        "hypothesis_id": "H4",
        "n_iterations": 300,
        "effect_size": 0.0,
        "power": 0.0,
        "converged": true,
        "parameters": {}
      }
    ]
  },
  "protocols": [
    {
      "hypothesis_id": "H1",
      "prediction": "IF VDAC1 is reconstituted into supported lipid bilayers with Chol/CL molar ratios ranging from 0.5 to 10, THEN AFM imaging will reveal a monotonic increase in honeycomb array area fraction (f_h) from <0.15 at Chol/CL=0.5 to >0.70 at Chol/CL=10, with a Hill-type transition midpoint at Chol/CL \u2248 2-4.",
      "protocol": "Reconstitute purified human VDAC1 into supported lipid bilayers (POPC/POPE/CL/Chol at defined ratios) on mica via vesicle fusion. Image in fluid tapping-mode AFM (Bruker MultiMode 8) at sub-nm resolution. Quantify honeycomb lattice area fraction using autocorrelation analysis across \u226520 fields per condition, 5 Chol/CL ratios \u00d7 3 replicates. Timeline: 8-10 weeks.",
      "dose_ranges": {
        "CL": {
          "doses": [
            2.0,
            5.0,
            10.0,
            15.0,
            20.0
          ],
          "unit": "mol%;"
        },
        "Cholesterol": {
          "doses": [
            5.0,
            10.0,
            20.0,
            30.0,
            40.0
          ],
          "unit": "mol%"
        }
      },
      "readouts": [
        "AFM topography (honeycomb lattice area fraction",
        "nearest-neighbor distance",
        "defect density)",
        "laurdan generalized polarization (membrane order)",
        "DLS for vesicle QC"
      ],
      "controls": [
        "VDAC1-free bilayers (same lipid compositions)",
        "POPC-only bilayers + VDAC1",
        "heat-denatured VDAC1",
        "scrambled lipid order (rapid freeze-thaw)",
        "---",
        "##"
      ],
      "expected_outcome": "Sigmoidal relationship between Chol/CL and f_h; lattice spacing ~6-7 nm consistent with published honeycomb periodicity; CL titration at fixed Chol causes",
      "null_outcome": "No correlation between Chol/CL and f_h; honeycomb arrays persist at Chol/CL=0.5; or arrays never form regardless of ratio, indicating protein-protein contacts dominate over lipid environment."
    },
    {
      "hypothesis_id": "H2",
      "prediction": "IF HK-II is displaced from VDAC1 honeycomb arrays (by glucose-6-phosphate or clotrimazole treatment), THEN within 10-30 minutes: (a) CL-specific fluorescent probe (NAO or TopFluor-CL) signal at VDAC clusters increases \u22652-fold, and (b) honeycomb array area fraction decreases by \u226540%, and (c) both effects are abolished by prior CL depletion (PLS3 knockdown or CL synthase inhibition).",
      "protocol": "Use isolated rat liver mitochondria or U2OS cells expressing VDAC1-GFP. Displace HK-II with clotrimazole (5-30 \u03bcM) or G6P (2-10 mM). Monitor CL exposure via NAO fluorescence (confocal, FRET-based) and VDAC organization via STORM/PALM super-resolution or AFM on isolated OMM sheets. CL-depletion arm: pre-treat with CLS1 inhibitor or siRNA 48h prior. Timeline: 12-16 weeks.",
      "dose_ranges": {
        "Clotrimazole": {
          "doses": [
            1.0,
            5.0,
            10.0,
            20.0,
            30.0
          ],
          "unit": "\u03bcM;"
        },
        "G6P": {
          "doses": [
            0.5,
            2.0,
            5.0,
            10.0
          ],
          "unit": "mM;"
        },
        "CLS1 siRNA": {
          "doses": [
            10.0,
            30.0
          ],
          "unit": "nM"
        }
      },
      "readouts": [
        "NAO fluorescence intensity at mitochondria (confocal)",
        "VDAC1 cluster size/density (STORM)",
        "HK-II co-IP or proximity ligation assay",
        "cytochrome c release (ELISA)",
        "\u0394\u03a8m (TMRE)"
      ],
      "controls": [
        "Vehicle-treated mitochondria",
        "HK-II-free VDAC1 (HK-II KO cells)",
        "non-displaceable HK-II mutant (VDAC1-E73Q)",
        "CL-replete vs CL-depleted matched pairs",
        "clotrimazole + exogenous CL rescue",
        "---",
        "##"
      ],
      "expected_outcome": "HK-II displacement causes rapid CL unmasking at VDAC sites (NAO increase), followed by honeycomb disassembly (reduced cluster size in STORM); CL-depleted mitochondria show HK-II displacement but no array disruption, proving CL is the mediating lipid.",
      "null_outcome": "HK-II displacement occurs but CL exposure does not change; or honeycomb arrays disassemble equally in CL-depleted mitochondria; or no detectable honeycomb structures exist in native OMM under any condition."
    },
    {
      "hypothesis_id": "H3",
      "prediction": "IF CBD (1-10 \u03bcM) is added to VDAC1-containing reconstituted bilayers, THEN honeycomb array density will change by \u226530% at concentrations below the Kd for direct VDAC binding (11 \u03bcM), AND this effect will be reproduced by a membrane-order-matched control compound (e.g., cholesterol hemisuccinate or vitamin E) that does not bind VDAC, AND will NOT be abolished by VDAC1 point mutations (e.g., E73Q, T19A) that disrupt known drug-binding pockets.",
      "protocol": "Reconstitute VDAC1 (WT and E73Q, T19A mutants) into supported bilayers (OMM-mimetic: POPC/POPE/CL/Chol 48:28:10:14). Treat with CBD (0.5, 1, 3, 5, 10, 30 \u03bcM), simvastatin (1, 5, 10, 30 \u03bcM), vitamin E (logP-matched non-VDAC-binder), and cholesterol hemisuccinate. Image by AFM; measure membrane order by laurdan GP spectroscopy in parallel GUVs. Timeline: 10-14 weeks.",
      "dose_ranges": {
        "CBD": {
          "doses": [
            0.5,
            1.0,
            3.0,
            5.0,
            10.0,
            30.0
          ],
          "unit": "\u03bcM;"
        },
        "Simvastatin": {
          "doses": [
            1.0,
            5.0,
            10.0,
            30.0
          ],
          "unit": "\u03bcM;"
        },
        "Vitamin E": {
          "doses": [
            1.0,
            5.0,
            10.0,
            30.0
          ],
          "unit": "\u03bcM;"
        },
        "CHS": {
          "doses": [
            1.0,
            5.0,
            10.0
          ],
          "unit": "\u03bcM"
        }
      },
      "readouts": [
        "AFM (f_h",
        "lattice parameter",
        "defect density)",
        "laurdan GP (membrane order)",
        "ITC (confirm binding/non-binding of controls to VDAC)",
        "FCS (VDAC diffusion coefficient)",
        "mass spectrometry (drug partitioning into bilayer)"
      ],
      "controls": [
        "5.0-7.0 (uniform)",
        "- bilayer_thickness_change: -0.5-1.0 nm (normal",
        "\u03bc=0.2",
        "\u03c3=0.3)",
        "- partition_coefficient_OMM: 100-10000 (log-uniform)",
        "TESTABILITY: 7",
        "PROTOCOL: Reconstitute VDAC1 (WT and E73Q",
        "T19A mutants) into supported bilayers (OMM-mimetic: POPC/POPE/CL/Chol 48:28:10:14). Treat with CBD (0.5",
        "1",
        "3",
        "5",
        "10",
        "30 \u03bcM)",
        "simvastatin (1",
        "5",
        "10",
        "30 \u03bcM)",
        "vitamin E (logP-matched non-VDAC-binder)",
        "and cholesterol hemisuccinate. Image by AFM",
        "measure membrane order by laurdan GP spectroscopy in parallel GUVs. Timeline: 10-14 weeks.",
        "EXPECTED OUTCOME: CBD at 1-5 \u03bcM (sub-Kd) alters f_h by \u226530%",
        "vitamin E at equi-partitioning concentration produces similar effect",
        "VDAC binding-site mutants show identical f_h shifts as WT",
        "confirming membrane-mediated mechanism. Laurdan GP correlates with f_h across all compounds.",
        "NULL OUTCOME: CBD effects on f_h only appear at >Kd concentrations",
        "VDAC binding-site mutants are resistant to CBD-induced reorganization",
        "logP-matched non-binders have no effect",
        "or laurdan GP changes do not correlate with array changes",
        "indicating direct binding is necessary.",
        "DOSE RANGES: CBD: 0.5",
        "1",
        "3",
        "5",
        "10",
        "30 \u03bcM",
        "Simvastatin: 1",
        "5",
        "10",
        "30 \u03bcM",
        "Vitamin E: 1",
        "5",
        "10",
        "30 \u03bcM",
        "CHS: 1",
        "5",
        "10 \u03bcM",
        "READOUTS: AFM (f_h",
        "lattice parameter",
        "defect density)",
        "laurdan GP (membrane order)",
        "ITC (confirm binding/non-binding of controls to VDAC)",
        "FCS (VDAC diffusion coefficient)",
        "mass spectrometry (drug partitioning into bilayer)",
        "CONTROLS: Vehicle (0.1% DMSO)",
        "protein-free bilayers + drugs (membrane-only effect)",
        "VDAC WT vs mutants at each drug dose",
        "heat-denatured VDAC",
        "cholesterol-only bilayers (no CL)",
        "---",
        "##"
      ],
      "expected_outcome": "CBD at 1-5 \u03bcM (sub-Kd) alters f_h by \u226530%; vitamin E at equi-partitioning concentration produces similar effect; VDAC binding-site mutants show identical f_h shifts as WT, confirming membrane-mediated mechanism. Laurdan GP correlates with f_h across all compounds.",
      "null_outcome": "CBD effects on f_h only appear at >Kd concentrations; VDAC binding-site mutants are resistant to CBD-induced reorganization; logP-matched non-binders have no effect; or laurdan GP changes do not correlate with array changes, indicating direct binding is necessary."
    },
    {
      "hypothesis_id": "H4",
      "prediction": "IF the honeycomb-to-dispersed transition is the rate-limiting step for apoptosis, THEN: (a) pre-dispersing VDAC arrays (by CL enrichment or cholesterol extraction with M\u03b2CD) will accelerate cytochrome c release by \u22653-fold compared to apoptotic stimulus alone, (b) artificially stabilizing honeycombs (cholesterol loading) will delay cytochrome c release by \u22653-fold even in the presence of BH3-only protein activation, and (c) the time from stimulus to cytochrome c release will correlate with f_h decay kinetics (r\u00b2 > 0.7) rather than with Bax/Bak activation kinetics.",
      "protocol": "",
      "dose_ranges": {},
      "readouts": [],
      "controls": [],
      "expected_outcome": "",
      "null_outcome": ""
    }
  ],
  "budget": {
    "s1_calls": 5,
    "s2_calls": 0,
    "verify_calls": 10,
    "gate_calls": 1,
    "s4_calls": 1,
    "s5_calls": 0,
    "total_calls": 17,
    "budget_target": "92-142 calls"
  },
  "audit_trail": {
    "session_seed": 1771019150,
    "s2_rounds": [],
    "s3_gate": {
      "stage": "S3",
      "passed": true,
      "convergence_score": 0.9047,
      "convergence_threshold": 0.85,
      "convergence_pass": true,
      "jaccard": 0.6523,
      "jaccard_threshold": 0.85,
      "jaccard_pass": false,
      "type_01_ratio": 0.8,
      "type_01_threshold": 0.75,
      "type_pass": true,
      "cosine": 0.9047,
      "jsd": 0.1801,
      "kappa": 0.9333,
      "type_distribution": {
        "0": 0.65,
        "1": 0.15,
        "2": 0.0,
        "3": 0.2
      }
    },
    "final_claims": [
      {
        "statement": "The Chol/CL ratio is a primary determinant of the honeycomb-vs-dispersed VDAC1 equilibrium in reconstituted and native OMM.",
        "type": 1,
        "confidence": 0.78,
        "mechanism": "Cholesterol increases membrane thickness and order stabilizing tight VDAC-VDAC lateral packing, while cardiolipin's conical geometry and negative curvature stress destabilize hexagonal arrays.",
        "falsifiable_by": "AFM imaging showing honeycomb persistence at high CL/low Chol ratios, or no dose-dependent array disruption with CL titration.",
        "model": "claude"
      },
      {
        "statement": "The proposed threshold equation Threshold = K/[(1-f_HKII)(1-f_BclxL)]*(Chol/CL) is a plausible phenomenological model but is not yet experimentally validated as written \u2014 the multiplicative separability of protein and lipid terms is an assumption.",
        "type": 3,
        "confidence": 0.4,
        "mechanism": "The equation assumes independent modular contributions of HK-II displacement, Bcl-xL removal, and lipid composition, which likely exhibit non-linear coupling.",
        "falsifiable_by": "Systematic measurement of apoptotic threshold across factorial combinations of f_HKII, f_BclxL, and Chol/CL showing non-separable interaction terms.",
        "model": "claude"
      },
      {
        "statement": "HK-II displacement unmasks VDAC N-terminal and membrane-proximal regions that preferentially recruit or stabilize cardiolipin, thereby locally shifting the lipid environment toward array disruption.",
        "type": 2,
        "confidence": 0.55,
        "mechanism": "HK-II's cytoplasmic footprint on VDAC1 occludes lipid-protein interfaces; removal exposes surfaces with CL affinity, nucleating CL-enriched microdomains that disassemble honeycomb packing.",
        "falsifiable_by": "MD simulations or CL-binding assays showing no difference in local CL enrichment \u00b1 HK-II; AFM showing HK-II removal does not change array density.",
        "model": "claude"
      },
      {
        "statement": "Lipophilic drugs (CBD, statins) can alter VDAC supramolecular organization through membrane order perturbation independent of direct VDAC binding, constituting a genuine but uncharacterized pharmacological mechanism.",
        "type": 3,
        "confidence": 0.5,
        "mechanism": ".",
        "falsifiable_by": "AFM of VDAC arrays in membranes \u00b1 CBD showing no change in lattice density; or showing all effects are abolished by VDAC point mutations that block CBD binding.",
        "model": "claude"
      },
      {
        "statement": "VDAC oligomerization into cytochrome c-releasing pores occurs exclusively from the dispersed (non-honeycomb) state, making array disassembly the rate-limiting step and physical point-of-no-return.",
        "type": 2,
        "confidence": 0.6,
        "mechanism": "Honeycomb geometry locks VDAC into non-oligomeric interfaces; only freed monomers can reorient into the distinct oligomeric contacts required for pore formation.",
        "falsifiable_by": "Evidence of oligomeric/apoptotic VDAC pores forming directly within intact honeycomb arrays; or kinetic data showing oligomerization is faster than array dissolution. \u2500\u2500\u2500",
        "model": "claude"
      },
      {
        "statement": "The Chol/CL ratio in the OMM physically determines the fraction of VDAC1 in honeycomb vs. dispersed states, and this ratio is mechanistically embedded in the apoptotic threshold equation.",
        "type": 1,
        "confidence": 0.85,
        "mechanism": "Cholesterol stabilizes honeycomb arrays via lipid packing, while cardiolipin disrupts them by introducing negative curvature, shifting VDAC1 to oligomerization-competent monomers.",
        "falsifiable_by": "Observing VDAC1 honeycomb persistence in high-CL membranes *without* cholesterol, or failure of the threshold equation to predict apoptosis in cells with experimentally clamped Chol/CL ratios.",
        "model": "mistral"
      },
      {
        "statement": "HK-II displacement from VDAC1 promotes honeycomb disassembly by unmasking cardiolipin microdomains, converting protected arrays into oligomerization-competent monomers.",
        "type": 2,
        "confidence": 0.7,
        "mechanism": "HK-II binding sterically shields cardiolipin; its removal exposes cardiolipin, which disrupts honeycombs and frees VDAC1 for oligomerization.",
        "falsifiable_by": "HK-II mutants that bind VDAC1 but do not mask cardiolipin failing to prevent honeycomb disassembly, or cardiolipin depletion blocking HK-II displacement effects.",
        "model": "mistral"
      },
      {
        "statement": "Lipophilic drugs (e.g., CBD, statins) alter VDAC1 supramolecular organization by changing local membrane order, independent of direct protein binding.",
        "type": 3,
        "confidence": 0.6,
        "mechanism": "High-logP drugs partition into the OMM, altering lipid packing/order and indirectly destabilizing honeycomb arrays via membrane fluidity changes.",
        "falsifiable_by": "Drugs with similar logP but no membrane-ordering effects failing to alter VDAC1 organization, or direct binding (e.g., via cryo-EM) being necessary for observed effects.",
        "model": "mistral"
      },
      {
        "statement": "The honeycomb-to-dispersed transition is the physical \"point of no return\" for VDAC-mediated apoptosis, with membrane reorganization as the rate-limiting step.",
        "type": 2,
        "confidence": 0.75,
        "mechanism": "Oligomerization (and thus apoptosis) requires dispersed VDAC1 monomers; honeycomb arrays are kinetically trapped and non-oligomerization-competent.",
        "falsifiable_by": "Observing apoptosis initiation from honeycomb arrays (e.g., via forced oligomerization in AFM), or drugs that bypass membrane reorganization to trigger apoptosis. --- \u2500\u2500\u2500",
        "model": "mistral"
      },
      {
        "statement": "Chol/CL ratio physically determines VDAC1 fraction in honeycomb (protected) vs. dispersed (oligomerization-competent) states, forming biophysical basis of threshold equation.",
        "type": 2,
        "confidence": 0.85,
        "mechanism": "Cholesterol/PE rigidify OMM domains stabilizing 2D honeycomb crystals (AFM data), while CL fluidizes/promotes disassembly to monomers at contact sites.",
        "falsifiable_by": "AFM on OMM liposomes varying Chol/CL showing no correlation between ratio and f_h, or MD simulations contradicting stability.",
        "model": "grok"
      },
      {
        "statement": "HK-II displacement from VDAC1 unmasks CL microdomains, promoting honeycomb disassembly to oligomerization-competent monomers.",
        "type": 3,
        "confidence": 0.65,
        "mechanism": "HK-II shields CL-rich domains (stabilizing arrays); release exposes CL, driving lipid phase separation and array breakup per 2024-2025 studies.",
        "falsifiable_by": "HK-II knockout mitochondria retaining honeycomb under pro-apoptotic stimuli, or FRET showing no CL exposure post-displacement.",
        "model": "grok"
      },
      {
        "statement": "Lipophilic drugs like CBD (logP 6.3; Kd=11\u03bcM) or statins (logP 4-5) alter VDAC organization by increasing OMM order/fluidity independent of direct binding.",
        "type": 3,
        "confidence": 0.7,
        "mechanism": "High logP drugs partition into OMM, mimicking cholesterol to stabilize honeycomb or disrupt CL domains via local packing changes (MD-predictable).",
        "falsifiable_by": "VDAC-binding mutants insensitive to drug but retaining organization changes, or GUV-AFM showing no assembly shift at [CBD]=1-10\u03bcM without Kd interaction.",
        "model": "grok"
      },
      {
        "statement": "Honeycomb\u2192dispersed transition instantiates apoptotic point of no return, with oligomerization restricted to dispersed monomers (membrane reorganization rate-limiting).",
        "type": 2,
        "confidence": 0.75,
        "mechanism": "Dense arrays sterically hinder protomer rearrangement needed for hexameric pores; dispersion at CL sites enables kinetics (AFM/MD evidence).",
        "falsifiable_by": "Oligomerization in intact honeycomb via cross-linking or mutagenesis, or live-cell super-res showing pores in undisrupted arrays. \u2500\u2500\u2500",
        "model": "grok"
      },
      {
        "statement": "The OMM Chol/CL ratio is a primary determinant of the apoptotic threshold by physically controlling the fraction of VDAC1 sequestered in apoptosis-resistant honeycomb arrays versus dispersed, oligomerization-competent monomers.",
        "type": 1,
        "confidence": 0.9,
        "mechanism": "Cholesterol stabilizes the ordered lipid environment required for dense honeycomb packing, while cardiolipin's unique conical shape and charge disrupt this order, favoring a dispersed monomeric state.",
        "falsifiable_by": "Observing no significant change in VDAC1 honeycomb prevalence in reconstituted membranes or in engineered cells where the OMM Chol/CL ratio is varied over a physiological range.",
        "model": "gemini"
      },
      {
        "statement": "Lipophilic drugs like CBD can trigger VDAC1-mediated apoptosis primarily by altering local membrane fluidity and order, thereby destabilizing cholesterol-rich honeycomb domains, rather than through direct, high-affinity binding to VDAC1.",
        "type": 2,
        "confidence": 0.75,
        "mechanism": "The drug partitions into the OMM, acting as a chaotropic (disordering) agent that lowers the energy barrier for cardiolipin to disrupt VDAC1 arrays, effectively lowering the apoptotic threshold.",
        "falsifiable_by": "Demonstrating that a hydrophilic CBD analog with an identical VDAC1 Kd (if one could be made) produces an equivalent pro-apoptotic effect, or that CBD fails to alter membrane order at concentrations that induce apoptosis.",
        "model": "gemini"
      },
      {
        "statement": "The dissociation of HK-II from VDAC1 is a critical sensitizing step that unmasks local cardiolipin pools, initiating the honeycomb-to-dispersed transition and committing the cell to apoptosis.",
        "type": 2,
        "confidence": 0.7,
        "mechanism": "HK-II binding sterically shields or locally sequesters cardiolipin, and its removal exposes VDAC1 to cardiolipin's disruptive effects, triggering disassembly of the protective array.",
        "falsifiable_by": "High-resolution imaging showing that VDAC1 arrays remain stable after HK-II dissociation in cells where cardiolipin is depleted or its interaction with VDAC1 is blocked. \u2500\u2500\u2500",
        "model": "gemini"
      },
      {
        "statement": "The Chol/CL ratio is a primary physical determinant of the VDAC1 honeycomb-vs-monomer equilibrium, and this lipid-driven partitioning provides the biophysical foundation for the apoptotic threshold equation.",
        "type": 1,
        "confidence": 0.75,
        "mechanism": "Cholesterol and PE promote ordered lipid phases that stabilize VDAC1 lattice contacts, while cardiolipin disrupts these contacts via headgroup charge and packing, creating a tunable equilibrium.",
        "falsifiable_by": "Demonstrating in reconstituted systems that the threshold for oligomerization is independent of Chol/CL ratio over a physiologically relevant range.",
        "model": "deepseek"
      },
      {
        "statement": "HK-II binding stabilizes honeycomb arrays by masking/displacing cardiolipin from VDAC's vicinity; its displacement unmasks cardiolipin microdomains, promoting lattice disassembly.",
        "type": 2,
        "confidence": 0.7,
        "mechanism": "HK-II's membrane-binding domain competes with cardiolipin for interaction sites near VDAC, so HK-II release increases local cardiolipin availability, destabilizing the array.",
        "falsifiable_by": "Showing that HK-II displacement does not alter local cardiolipin accessibility or that honeycomb stability is unchanged after HK-II removal in a cardiolipin-free system.",
        "model": "deepseek"
      },
      {
        "statement": "Lipophilic drugs with logP >4 can alter VDAC supramolecular organization indirectly by modulating local membrane order and lipid partitioning, constituting a distinct, non-canonical pharmacological mechanism.",
        "type": 1,
        "confidence": 0.8,
        "mechanism": ".",
        "falsifiable_by": "Demonstrating that such drugs, at therapeutic concentrations, cause no change in VDAC organization in lipid-only reconstitutions without direct protein binding.",
        "model": "deepseek"
      },
      {
        "statement": "The honeycomb-to-dispersed transition is the physical rate-limiting step for VDAC-mediated apoptosis, as oligomerization is only permissible from the dispersed state.",
        "type": 2,
        "confidence": 0.65,
        "mechanism": "The honeycomb array sterically and allosterically inhibits pro-apoptotic oligomerization; disassembly unlocks this conformational capability.",
        "falsifiable_by": "Observing VDAC oligomerization and cytochrome c release directly from intact honeycomb arrays without prior lattice disassembly. \u2500\u2500\u2500",
        "model": "deepseek"
      }
    ]
  }
}